- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.09. | Prostatype Genomics AB: Prostatype Genomics provides update on the Medicare process regarding Prostatype | 258 | GlobeNewswire (Europe) | Prostatype Genomics AB today provides an update regarding the ongoing process for Medicare reimbursement for Prostatype® in the US. The process is continuing, and the dialogue is now focused on a limited... ► Artikel lesen | |
| 17.09. | Prostatype Genomics AB: Prostatype Genomics AB receives approximately SEK 12.5 million through the exercise of warrants of series TO6 | 373 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA... ► Artikel lesen | |
| 31.08. | Prostatype Genomics AB H1 Loss Declines | 1 | RTTNews | ||
| 31.08. | Prostatype Genomics AB: Prostatype Genomics publishes its interim report for the first half of 2026 | 636 | GlobeNewswire (Europe) | Prostatype Genomics AB today publishes its interim report for the first half of 2026. The full interim report is attached and can also be downloaded from the company's website, www.prostatypegenomics.com.
First... ► Artikel lesen | |
| 11.08. | New equity right for trading, Prostatype Genomics AB | 387 | GlobeNewswire | At the request of Prostatype Genomics AB, equity rights will be traded on First North Growth Market as from 12 August 2026.
Security name:
Prostatype Genomics AB... ► Artikel lesen | |
| 04.08. | New last trading day for paid subscription shares (BTA) of Prostatype Genomics AB | 289 | GlobeNewswire | At the request of Prostatype Genomics AB, the last trading day in Prostatype Genomics AB's
paid subscription shares will be changed from
2026-08-10 to 2026-08-06.
Instrument: Paid subscription... ► Artikel lesen | |
| PROSTATYPE GENOMICS Aktie jetzt für 0€ handeln | |||||
| 27.07. | Prostatype Genomics AB: Prostatype Genomics AB announces outcome in rights issue of units | 283 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA... ► Artikel lesen | |
| 21.07. | Prostatype Genomics AB: Last day for subscription in Prostatype Genomics AB's rights issue of units is July 23, 2026 | 345 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA... ► Artikel lesen | |
| 09.07. | Prostatype Genomics AB: The subscription period in Prostatype Genomics AB's rights issue of units begins today | 443 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA... ► Artikel lesen | |
| 08.07. | Listing of units rights and paid subscription units of Prostatype Genomics AB | 337 | GlobeNewswire | With effect from July 09, 2026, the units rights in Prostatype Genomics AB will be traded on First North Growth Market. Trading will continue up until and including July 20, 2026.
... ► Artikel lesen | |
| 03.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.07.2026 | 1.378 | Xetra Newsboard | Das Instrument OCI US00089H1068 ACS A.DE C.ADR 1/5/EO-,50 EQUITY wird cum Kapitalmassnahme gehandelt am 03.07.2026 und ex Kapitalmassnahme am 06.07.2026 The instrument OCI US00089H1068 ACS A.DE C.ADR... ► Artikel lesen | |
| 22.06. | Prostatype Genomics AB: Bulletin From Annual General Meeting In Prostatype Genomics AB (publ) | 201 | GlobeNewswire (Europe) | The annual general meeting in Prostatype Genomics AB (publ), corp. reg. no 556726-0285 (the "Company") was held on 22 June 2026. Below is a summary of the resolutions adopted. All resolutions were adopted... ► Artikel lesen | |
| 25.05. | Prostatype Genomics AB: Update from Prostatype Genomics Regarding the Medicare Reimbursement Process for Prostatype in the United States | 519 | GlobeNewswire (Europe) | Prostatype Genomics has been actively engaged in the process regarding Medicare reimbursement for Prostatype® in the United States for some time. The process is currently in an intensive phase and continues... ► Artikel lesen | |
| 19.05. | Prostatype Genomics AB: Prostatype Genomics AB announces the Board of Directors' intention to resolve on a rights issue of units of approximately SEK 47.4 million | 402 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA... ► Artikel lesen | |
| 26.02. | Prostatype Genomics AB: Prostatype Genomics publishes year-end report for 2025 | 465 | GlobeNewswire (Europe) | Prostatype Genomics AB today publishes its year-end report for the full year 2025, including the interim report for the second half of 2025. The full year-end report is attached and can also be downloaded... ► Artikel lesen | |
| 11.11.25 | Prostatype Genomics AB: Previous Investments in Research and Development Unlock Hidden Assets in Prostatype Genomics | 421 | GlobeNewswire (Europe) | Alongside Prostatype Genomics (the "Company") strategic focus on the U.S. market and continued efforts to secure Medicare reimbursement, the Company has continuously invested in research and development... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,030 | -1,01 % | Siemens Healthineers sortiert sein Geschäft neu | Siemens Healthineers setzt einen ungewöhnlich klaren Schnitt im Ultraschallgeschäft. Statt weiterhin möglichst viele medizinische Anwendungen abzudecken, konzentriert sich der Konzern künftig stärker... ► Artikel lesen | |
| ECKERT & ZIEGLER | 12,920 | +1,33 % | Eckert & Ziegler: Independence gains value: Recent radiopharma transactions highlight the strategic value of EUZ's independent ... | Recent radiopharma acquisitions underline the value of EUZ's core capabilities: independent isotope supply and specialist manufacturing. Strategic and financial investors are acquiring comparable isotope... ► Artikel lesen | |
| MORE LIFE COMPANY | 0,032 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 24.08.2026 | The following instruments on XETRA do have their first trading 24.08.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 24.08.2026
Aktien
1 CA0966311064 Boardwalk Real Estate... ► Artikel lesen | |
| CYTOSORBENTS | 4,870 | 0,00 % | Cytosorbents Corp: CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement | PRINCETON, N.J., Sept. 23, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac... ► Artikel lesen | |
| MEDARTIS | 91,50 | -1,61 % | Medartis Holding AG: Medartis Group acquires M.A.R.C. Institute to establish its first surgical education center in the US | The center in Doral, Florida, becomes the Group's first permanent training facility outside Europe and, with 36 surgical stations, its largest
The center will... ► Artikel lesen | |
| GESUNDHEITSWELT CHIEMGAU | 11,000 | +5,77 % | EQS-Adhoc: Gesundheitswelt Chiemgau AG: Gesundheitswelt Chiemgau senkt Ergebnisprognose für das Geschäftsjahr 2026 aufgrund von einmaligen Sondereffekten von rund EUR 13,0 Mio. | EQS-Ad-hoc: Gesundheitswelt Chiemgau AG / Schlagwort(e): Prognose / Gesamtjahr
Gesundheitswelt Chiemgau AG senkt Ergebnisprognose für das Geschäftsjahr 2026 aufgrund von... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,040 | -1,26 % | Fresenius Medical Care AG: Kurzfristige Gegenwinde zunehmend eingepreist; Hochstufung auf KAUFEN | Fresenius Medical Care (FME) hat die Prognose für das Geschäftsjahr 2026 bestätigt, wobei auslaufende TDAPA-Effekte, schwache Behandlungsvolumina in den USA und Restrukturierungsaufwendungen das Ergebnis... ► Artikel lesen | |
| FRESENIUS | 44,905 | -0,38 % | EQS-News: Fresenius SE & Co. KGaA: Aufsichtsrat beruft Dr. Marc-Alexander Mahl in den Vorstand und verlängert Vertrag von Sara Hennicken | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Personalie
Aufsichtsrat beruft Dr. Marc-Alexander Mahl in den Vorstand und verlängert Vertrag von Sara Hennicken (News mit Zusatzmaterial)
15.10.2026... ► Artikel lesen | |
| GERRESHEIMER | 32,720 | +7,49 % | EQS-News: Gerresheimer AG: Gerresheimer steigert EcoVadis-Ratingergebnis und wird erneut mit Gold ausgezeichnet | EQS-News: Gerresheimer AG
/ Schlagwort(e): Nachhaltigkeit/ESG
Gerresheimer steigert EcoVadis-Ratingergebnis und wird erneut mit Gold ausgezeichnet
14.10.2026 / 10:00 CET/CEST
Für... ► Artikel lesen | |
| HEARTFLOW | 51,01 | -0,02 % | Heartflow, Inc.: Heartflow to Report Third Quarter 2026 Financial Results on November 12, 2026 | ||
| BILLIONTOONE | 101,03 | 0,00 % | BillionToOne, Inc.: BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026 | ||
| BRIGHTSPRING HEALTH SERVICES | 61,25 | -0,07 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| GENEDX | 66,32 | +0,05 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| MIMEDX | 4,380 | 0,00 % | Sanara MedTech/MiMedx deal spread widens on FTC second request | ||
| ALIGNMENT HEALTHCARE | 8,415 | +0,18 % | Alignment Healthcare USA, LLC: Alignment Health Plan and Astrana Health Partner to Expand Access to Trusted Local Care for California Seniors |
Das Unternehmen PROSTATYPE GENOMICS AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,007 Euro und damit -5,56 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROSTATYPE GENOMICS AB finden Sie auf Wallstreet Online.